Scarica l'app Stockscreener
4.87
0.00%
0.00
Dopo l'orario di chiusura:
4.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.87
Aprire:
$4.86
Volume 24 ore:
1.01M
Relative Volume:
0.53
Capitalizzazione di mercato:
$471.04M
Reddito:
Utile/perdita netta:
$-81.49M
Rapporto P/E:
-6.0198
EPS:
-0.809
Flusso di cassa netto:
$-73.48M
1 W Prestazione:
+12.47%
1M Prestazione:
+15.40%
6M Prestazione:
+33.79%
1 anno Prestazione:
-41.11%
Intervallo 1D:
$4.72
$4.91
Intervallo di 1 settimana:
$4.1501
$4.91
Portata 52W:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Nome
Rezolute Inc
Settore
Industria
Telefono
650-206-4507
Indirizzo
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
4.87 | 471.04M | 0 | -81.49M | -73.48M | -0.809 |
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-06 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2026-09-30 | Iniziato | Lake Street | Buy |
| 2026-09-29 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2026-06-03 | Aggiornamento | Citizens | Mkt Perform → Mkt Outperform |
| 2026-03-25 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-12-11 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | Downgrade | Craig Hallum | Buy → Hold |
| 2025-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-08-27 | Iniziato | Guggenheim | Buy |
| 2024-07-17 | Iniziato | BTIG Research | Buy |
| 2024-06-04 | Iniziato | Craig Hallum | Buy |
| 2024-04-09 | Iniziato | Maxim Group | Buy |
| 2022-08-02 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-09-08 | Iniziato | ROTH Capital | Buy |
| 2021-05-27 | Iniziato | Oppenheimer | Outperform |
| 2021-05-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Rezolute Inc Borsa (RZLT) Ultime notizie
A December 2 shareholder vote could expand Rezolute (RZLT)'s authorized common shares. - Stock Titan
Rezolute, Inc. expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Rezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset - Seeking Alpha
Rezolute (RZLT) FDA Review Highlights Uncertain Path Amid Cash-F - GuruFocus
Rezolute says late-stage trial data for lead asset remains under FDA review - TradingView
Rezolute awaits FDA feedback on congenital HI treatment data By Investing.com - Investing.com Nigeria
Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint - Yahoo Finance
Rezolute (RZLT) Updates FDA Review of Phase 3 Data Amid Unprofitable Status - GuruFocus
Rezolute awaits FDA feedback on congenital HI treatment data By Investing.com - Investing.com Canada
Rezolute awaits FDA feedback on congenital HI treatment data - investing.com
Rezolute awaits FDA feedback on congenital HI treatment data By Investing.com - Investing.com India
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism - The Manila Times
Rezolute awaits FDA feedback on congenital HI treatment data By Investing.com - Investing.com UK
RZLT Q4'26 Earnings: EPS estimate is (0.15) USD - TradingView
FDA is still reviewing Rezolute’s experimental drug. No timeline is set. - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Rezolute (RZLT) CCO sells stock to cover RSU taxes - stocktitan.net
RZLT Q4'26 Earnings: revenue estimate is 0 USD - tradingview.com
Rezolute (RZLT) Shares Decline 7% as Stock Approaches Key Support at $4.39Diagonal Spread Trade - vinanet.vn
Rezolute (RZLT) Shares Decline 7% as Stock Approaches Key Support at $4.39Insider Sentiment - dars.gov.et
Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Rezolute, Inc.'s (NASDAQ:RZLT) Shift From Loss To Profit - simplywall.st
Balyasny Asset Management L.P. Reduces Stake in Rezolute Inc (RZ - GuruFocus
Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Rezolute Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Bank of New York Mellon Corp Sells 481,913 Shares of Rezolute, Inc. $RZLT - MarketBeat
Rezolute Stock Price Forecast. Should You Buy RZLT? - StockInvest.us
Balyasny reports 4.84% Rezolute (RZLT) stake in Schedule 13G/A - Stock Titan
Rezolute, Inc. $RZLT Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Bank of America Corp (RZLT) discloses 1.2% Rezolute ownership in 13G/A - Stock Titan
Rezolute, Inc. (RZLT) gains 5.9% reported stake from Dellora Investments - Stock Titan
Rezolute Inc (RZLT) Stock News Today - TradingKey
Rezolute Inc (RZLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - The National Law Review
RZLT Q2 2026 Earnings: Loss Narrows 12.33% vs. Estimates; Shares Slip 3.28%Estimate Dispersion - vinanet.vn
Rezolute (RZLT) Pulls Back 5.4% as Biotech Volatility ResurfacesAggressive Growth Picks - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Boston Scientific (BSX) - The Globe and Mail
H.C. Wainwright Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $5 - moomoo.com
RZLT|Rezolute Inc|Price:4.930|Chg%:-0.060 - TradingKey
RZLT|Rezolute Inc|Price:4.990| - TradingKey
Rezolute Inc (RZLT) Balance Sheet - TradingKey
Rezolute Inc (RZLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rezolute Inc (RZLT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rezolute Inc (RZLT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rezolute Inc (RZLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rezolute Inc (RZLT) Institutional Confidence - TradingKey
Rezolute Inc (RZLT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RZLT|Rezolute Inc|Price:4.930|Chg%:-0.060 - TradingKey
Rezolute Inc (RZLT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rezolute Inc (RZLT) Income Statement - tradingkey.com
Rezolute Inc Azioni (RZLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rezolute Inc Azioni (RZLT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hogenhuis Wladimir | Director |
Dec 16 '25 |
Buy |
1.69 |
5,650 |
9,548 |
119,675 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Dec 16 '25 |
Buy |
1.70 |
28,000 |
47,600 |
308,352 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.77 |
40,000 |
70,640 |
415,900 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.79 |
5,000 |
8,938 |
7,000 |
| Elam Nevan C | CEO |
Dec 15 '25 |
Buy |
1.59 |
32,000 |
50,880 |
641,119 |
| Karnawat Sunil Ratilal | Chief Commercial Officer |
Dec 15 '25 |
Buy |
1.62 |
12,100 |
19,599 |
71,542 |
| Evans Daron | CFO |
Dec 09 '25 |
Buy |
5.04 |
10,549 |
53,167 |
131,900 |
1.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):